PURPOSE: To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia. PATIENTS AND METHODS: Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12. Sorafenib was continued until day 28 if tolerated. Two sorafenib dose levels (200 mg/m(2) and 150 mg/m(2) twice daily) were planned. Sorafenib pharmacokinetic and pharmacodynamic studies were performed on days 7 and 8. RESULTS: At sorafenib 200 mg/m(2), two of four patients in stratum one and one of two patients in stratum two had grade 3 hand-foot skin reaction and/or rash as dose-limiting toxicities (DLTs). No DLTs were observed in six patients in stratum one at sorafenib 150 mg/m(2). Sorafenib inhibited the phosphorylation of AKT, S6 ribosomal protein, and 4E-BP1 in leukemia cells. The rate of sorafenib conversion to its metabolite sorafenib N-oxide was high (mean, 33%; range, 17% to 69%). In vitro, the N-oxide potently inhibited FLT3-internal tandem duplication (ITD; binding constant, 70 nmol/L) and the viability of five AML cell lines. On day 8, sorafenib decreased blast percentages in 10 of 12 patients (median, 66%; range, 9% to 95%). After combination chemotherapy, six patients (three FLT3-ITD and three FLT3 wild-type AML) achieved complete remission, two (both FLT3-ITD AML) had complete remission with incomplete blood count recovery, and one (FLT3 wild-type AML) had partial remission. CONCLUSION: Sorafenib in combination with clofarabine and cytarabine is tolerable and shows activity in relapsed/refractory pediatric AML.
PURPOSE: To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia. PATIENTS AND METHODS: Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12. Sorafenib was continued until day 28 if tolerated. Two sorafenib dose levels (200 mg/m(2) and 150 mg/m(2) twice daily) were planned. Sorafenib pharmacokinetic and pharmacodynamic studies were performed on days 7 and 8. RESULTS: At sorafenib 200 mg/m(2), two of four patients in stratum one and one of two patients in stratum two had grade 3 hand-foot skin reaction and/or rash as dose-limiting toxicities (DLTs). No DLTs were observed in six patients in stratum one at sorafenib 150 mg/m(2). Sorafenib inhibited the phosphorylation of AKT, S6 ribosomal protein, and 4E-BP1 in leukemia cells. The rate of sorafenib conversion to its metabolite sorafenib N-oxide was high (mean, 33%; range, 17% to 69%). In vitro, the N-oxide potently inhibited FLT3-internal tandem duplication (ITD; binding constant, 70 nmol/L) and the viability of five AML cell lines. On day 8, sorafenib decreased blast percentages in 10 of 12 patients (median, 66%; range, 9% to 95%). After combination chemotherapy, six patients (three FLT3-ITD and three FLT3 wild-type AML) achieved complete remission, two (both FLT3-ITD AML) had complete remission with incomplete blood count recovery, and one (FLT3 wild-type AML) had partial remission. CONCLUSION:Sorafenib in combination with clofarabine and cytarabine is tolerable and shows activity in relapsed/refractory pediatric AML.
Authors: Lie Li; Ming Zhao; Fariba Navid; Keith Pratz; B Doug Smith; Michelle A Rudek; Sharyn D Baker Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2010-09-09 Impact factor: 3.205
Authors: Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart Journal: Nat Biotechnol Date: 2005-02-13 Impact factor: 54.908
Authors: Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker Journal: J Natl Cancer Inst Date: 2011-04-12 Impact factor: 13.506
Authors: Steven M Kornblau; Matthew Womble; Yi Hua Qiu; C Ellen Jackson; Wenjing Chen; Marina Konopleva; Elihu H Estey; Michael Andreeff Journal: Blood Date: 2006-06-08 Impact factor: 22.113
Authors: Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz Journal: Oncologist Date: 2007-04
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Bassem I Razzouk; Ching-Hon Pui; Stanley Pounds; Martin Andreansky; Frederick G Behm; Susana C Raimondi; Sheila A Shurtleff; James R Downing; Dario Campana Journal: Br J Haematol Date: 2003-10 Impact factor: 6.998
Authors: Andrea N Edginton; Eric I Zimmerman; Aksana Vasilyeva; Sharyn D Baker; John C Panetta Journal: Cancer Chemother Pharmacol Date: 2016-04-06 Impact factor: 3.333
Authors: Harina Vin; Grace Ching; Sandra S Ojeda; Charles H Adelmann; Vida Chitsazzadeh; David W Dwyer; Haiching Ma; Karin Ehrenreiter; Manuela Baccarini; Rosamaria Ruggieri; Jonathan L Curry; Ana M Ciurea; Madeleine Duvic; Naifa L Busaidy; Nizar M Tannir; Kenneth Y Tsai Journal: Mol Cancer Ther Date: 2013-10-29 Impact factor: 6.261
Authors: Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana Journal: Clin Cancer Res Date: 2012-11-08 Impact factor: 12.531